Preventive Misconception and Risk Behaviors in a Multinational HIV Prevention Trial

for the MTN-020/ASPIRE Study Team

Research output: Contribution to journalArticle

Abstract

Background: Some HIV prevention research participants may hold a “preventive misconception” (PM), an overestimate of the probability or level of personal protection afforded by trial participation. However, these reports typically rely upon small, retrospective qualitative assessments that did not use a standardized approach. Methods: We administered a measure of PM called PREMIS, during Microbicide Trials Network 020—A Study to Prevent Infection with a Ring for Extended Use, a large, multicenter, placebo-controlled, phase III trial evaluating the safety and efficacy of a dapivirine vaginal ring among women at risk for HIV infection in Malawi, South Africa, Uganda, and Zimbabwe. The maximum follow-up period was 2.6 years. Results: One thousand two hundred sixty-one respondents completed PREMIS at their month 3 visit (M3); 2085 at their month 12 visit (M12); and 1010 at both visits. Most participants expressed high expectations of personal benefit (EPB) and that at least one of the rings used in the trial would reduce the risk of getting HIV (expectation of maximum aggregate benefit or EMAB). There was a moderate positive correlation between EPB and EMAB at M3 (r =.43, 95% CI:.37,.47) and M12 (r =.44, 95% CI:.40,.48). However, there was variability among sites in the strength of the relationship. There was no relationship between either expectation variable and condom use, adherence, or HIV infection. Conclusions: A majority of trial participants expressed some belief that their risk of HIV infection would be reduced by using a vaginal ring, which may signal PM. However, such beliefs were not associated with adherence, condom use, or subsequent HIV infection, and there was variability across sites. Further work is needed to understand these findings.

Original languageEnglish (US)
Pages (from-to)79-87
Number of pages9
JournalAJOB Empirical Bioethics
Volume10
Issue number2
DOIs
StatePublished - Apr 3 2019

Fingerprint

Risk-Taking
risk behavior
HIV Infections
Female Contraceptive Devices
HIV
Condoms
Malawi
Zimbabwe
Uganda
South Africa
Anti-Infective Agents
Placebos
Safety
AIDS/HIV
Misconceptions
Infection
Research
participation
Ring

Keywords

  • attitudes
  • ethics
  • HIV prevention research
  • informed consent
  • Preventive misconception

ASJC Scopus subject areas

  • Health(social science)
  • Philosophy
  • Health Policy

Cite this

Preventive Misconception and Risk Behaviors in a Multinational HIV Prevention Trial. / for the MTN-020/ASPIRE Study Team.

In: AJOB Empirical Bioethics, Vol. 10, No. 2, 03.04.2019, p. 79-87.

Research output: Contribution to journalArticle

for the MTN-020/ASPIRE Study Team. / Preventive Misconception and Risk Behaviors in a Multinational HIV Prevention Trial. In: AJOB Empirical Bioethics. 2019 ; Vol. 10, No. 2. pp. 79-87.
@article{f8531825829147908cb05cacddf5dd64,
title = "Preventive Misconception and Risk Behaviors in a Multinational HIV Prevention Trial",
abstract = "Background: Some HIV prevention research participants may hold a “preventive misconception” (PM), an overestimate of the probability or level of personal protection afforded by trial participation. However, these reports typically rely upon small, retrospective qualitative assessments that did not use a standardized approach. Methods: We administered a measure of PM called PREMIS, during Microbicide Trials Network 020—A Study to Prevent Infection with a Ring for Extended Use, a large, multicenter, placebo-controlled, phase III trial evaluating the safety and efficacy of a dapivirine vaginal ring among women at risk for HIV infection in Malawi, South Africa, Uganda, and Zimbabwe. The maximum follow-up period was 2.6 years. Results: One thousand two hundred sixty-one respondents completed PREMIS at their month 3 visit (M3); 2085 at their month 12 visit (M12); and 1010 at both visits. Most participants expressed high expectations of personal benefit (EPB) and that at least one of the rings used in the trial would reduce the risk of getting HIV (expectation of maximum aggregate benefit or EMAB). There was a moderate positive correlation between EPB and EMAB at M3 (r =.43, 95{\%} CI:.37,.47) and M12 (r =.44, 95{\%} CI:.40,.48). However, there was variability among sites in the strength of the relationship. There was no relationship between either expectation variable and condom use, adherence, or HIV infection. Conclusions: A majority of trial participants expressed some belief that their risk of HIV infection would be reduced by using a vaginal ring, which may signal PM. However, such beliefs were not associated with adherence, condom use, or subsequent HIV infection, and there was variability across sites. Further work is needed to understand these findings.",
keywords = "attitudes, ethics, HIV prevention research, informed consent, Preventive misconception",
author = "{for the MTN-020/ASPIRE Study Team} and Jeremy Sugarman and Li Lin and Baeten, {Jared M.} and Thesla Palanee-Phillips and Brown, {Elizabeth R.} and {Matovu Kiweewa}, Flavia and Mgodi, {Nyaradzo M.} and Gonasagrie Nair and Samantha Siva and Seils, {Damon M.} and Weinfurt, {Kevin P.}",
year = "2019",
month = "4",
day = "3",
doi = "10.1080/23294515.2019.1593257",
language = "English (US)",
volume = "10",
pages = "79--87",
journal = "AJOB Empirical Bioethics",
issn = "2329-4515",
publisher = "Taylor and Francis Ltd.",
number = "2",

}

TY - JOUR

T1 - Preventive Misconception and Risk Behaviors in a Multinational HIV Prevention Trial

AU - for the MTN-020/ASPIRE Study Team

AU - Sugarman, Jeremy

AU - Lin, Li

AU - Baeten, Jared M.

AU - Palanee-Phillips, Thesla

AU - Brown, Elizabeth R.

AU - Matovu Kiweewa, Flavia

AU - Mgodi, Nyaradzo M.

AU - Nair, Gonasagrie

AU - Siva, Samantha

AU - Seils, Damon M.

AU - Weinfurt, Kevin P.

PY - 2019/4/3

Y1 - 2019/4/3

N2 - Background: Some HIV prevention research participants may hold a “preventive misconception” (PM), an overestimate of the probability or level of personal protection afforded by trial participation. However, these reports typically rely upon small, retrospective qualitative assessments that did not use a standardized approach. Methods: We administered a measure of PM called PREMIS, during Microbicide Trials Network 020—A Study to Prevent Infection with a Ring for Extended Use, a large, multicenter, placebo-controlled, phase III trial evaluating the safety and efficacy of a dapivirine vaginal ring among women at risk for HIV infection in Malawi, South Africa, Uganda, and Zimbabwe. The maximum follow-up period was 2.6 years. Results: One thousand two hundred sixty-one respondents completed PREMIS at their month 3 visit (M3); 2085 at their month 12 visit (M12); and 1010 at both visits. Most participants expressed high expectations of personal benefit (EPB) and that at least one of the rings used in the trial would reduce the risk of getting HIV (expectation of maximum aggregate benefit or EMAB). There was a moderate positive correlation between EPB and EMAB at M3 (r =.43, 95% CI:.37,.47) and M12 (r =.44, 95% CI:.40,.48). However, there was variability among sites in the strength of the relationship. There was no relationship between either expectation variable and condom use, adherence, or HIV infection. Conclusions: A majority of trial participants expressed some belief that their risk of HIV infection would be reduced by using a vaginal ring, which may signal PM. However, such beliefs were not associated with adherence, condom use, or subsequent HIV infection, and there was variability across sites. Further work is needed to understand these findings.

AB - Background: Some HIV prevention research participants may hold a “preventive misconception” (PM), an overestimate of the probability or level of personal protection afforded by trial participation. However, these reports typically rely upon small, retrospective qualitative assessments that did not use a standardized approach. Methods: We administered a measure of PM called PREMIS, during Microbicide Trials Network 020—A Study to Prevent Infection with a Ring for Extended Use, a large, multicenter, placebo-controlled, phase III trial evaluating the safety and efficacy of a dapivirine vaginal ring among women at risk for HIV infection in Malawi, South Africa, Uganda, and Zimbabwe. The maximum follow-up period was 2.6 years. Results: One thousand two hundred sixty-one respondents completed PREMIS at their month 3 visit (M3); 2085 at their month 12 visit (M12); and 1010 at both visits. Most participants expressed high expectations of personal benefit (EPB) and that at least one of the rings used in the trial would reduce the risk of getting HIV (expectation of maximum aggregate benefit or EMAB). There was a moderate positive correlation between EPB and EMAB at M3 (r =.43, 95% CI:.37,.47) and M12 (r =.44, 95% CI:.40,.48). However, there was variability among sites in the strength of the relationship. There was no relationship between either expectation variable and condom use, adherence, or HIV infection. Conclusions: A majority of trial participants expressed some belief that their risk of HIV infection would be reduced by using a vaginal ring, which may signal PM. However, such beliefs were not associated with adherence, condom use, or subsequent HIV infection, and there was variability across sites. Further work is needed to understand these findings.

KW - attitudes

KW - ethics

KW - HIV prevention research

KW - informed consent

KW - Preventive misconception

UR - http://www.scopus.com/inward/record.url?scp=85064713347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064713347&partnerID=8YFLogxK

U2 - 10.1080/23294515.2019.1593257

DO - 10.1080/23294515.2019.1593257

M3 - Article

C2 - 31002583

AN - SCOPUS:85064713347

VL - 10

SP - 79

EP - 87

JO - AJOB Empirical Bioethics

JF - AJOB Empirical Bioethics

SN - 2329-4515

IS - 2

ER -